Back to top
more

BeiGene (BGNE)

(Delayed Data from NSDQ)

$202.73 USD

202.73
551,774

-5.30 (-2.55%)

Updated Nov 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Waters Stock Gains on Earnings & Sales Beat in Q3, Raised View

by Zacks Equity Research

WAT's third-quarter 2024 results show growth in the pharma and industrial sectors. A dip in China sales creates headwinds.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

BeiGene (BGNE) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

BeiGene (BGNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Wall Street Analysts See a 27.84% Upside in BeiGene (BGNE): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 27.8% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BeiGene, Ltd. (BGNE) Just Flashed Golden Cross Signal: Do You Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Wall Street Analysts See a 40.85% Upside in BeiGene (BGNE): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 40.9% upside potential for BeiGene (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Travere (TVTX) Stock Jumps 5.2%: Will It Continue to Soar?

by Zacks Equity Research

Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study

by Zacks Equity Research

Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.

BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why

by Zacks Equity Research

Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.

BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

BeiGene's (BGNE) revenues in fourth-quarter 2023 are expected to have been driven by the sales of its marketed pharmaceutical products.

Ekta Bagri headshot

3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024

by Ekta Bagri

REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

Nalak Das headshot

Top 5 Momentum Picks for January After a Fabulous 2023

by Nalak Das

We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.

New Strong Buy Stocks for December 22nd

by Zacks Equity Research

DOYU, STLA, BGNE, LEGH and WTS have been added to the Zacks Rank #1 (Strong Buy) List on December 22, 2023.

Ekta Bagri headshot

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

by Ekta Bagri

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Nalak Das headshot

5 Nasdaq Composite Laggards Likely to Gather Pace in 2024

by Nalak Das

We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE.

Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for BeiGene, Ltd. (BGNE) points to a 44.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics

by Zacks Equity Research

Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Nalak Das headshot

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

by Nalak Das

We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.

Wall Street Analysts Believe BeiGene, Ltd. (BGNE) Could Rally 32.87%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 32.9% upside potential for BeiGene, Ltd. (BGNE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Prelude (PRLD) Collaborates With BeiGene for Oncology Candidate

by Zacks Equity Research

Prelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.

Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales

by Zacks Equity Research

Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.

Down -15.66% in 4 Weeks, Here's Why You Should You Buy the Dip in BeiGene, Ltd. (BGNE)

by Zacks Equity Research

BeiGene, Ltd. (BGNE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.